Peptides News and Research

RSS

Advances in the management of diabetes mellitus

The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.

1 Sep 2008

Takeda and Affymax provide update for Hematide in chemotherapy-induced anemia

Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.

28 Aug 2008

Dual-mode nanoparticles image tumors using MRI and PET

Medical imaging represents one of the most used and useful procedures in the oncologist's diagnostic toolkit, even though each of the most useful techniques-magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning-has its own set of limitations.

17 Aug 2008

Sngle-walled carbon nanotubes used as cancer drug delivery vehicles

The problem with using a shotgun to kill a housefly is that even if you get the pest, you'll likely do a lot of damage to your home in the process. Hence the value of the more surgical flyswatter.

14 Aug 2008

Genetic biomarker linked to subcutaneous growth hormone dose-response

The interindividual variability of response to subcutaneously applied protein-based drugs remains poorly understood. However, defining genetic markers that can be associated with biological effects of such drugs may improve the understanding of individual variability of response and even drug resistance.

6 Aug 2008

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).

4 Aug 2008

Immunotherapy shows promise in high-risk pediatric sarcomas

Based on a pilot study in children with sarcoma, researchers at the National Institutes of Health (NIH) believe that immunotherapy could prove beneficial in treating high-risk forms of this cancer.

3 Aug 2008

Promising new therapy for Alzheimer's

NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin (IGIV) for Alzheimer's disease at the Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Chicago.

From Baxter International Inc. 30 Jul 2008

Viagra and Levitra ED drugs shown to allow more chemo to reach brain tumors

In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.

28 Jul 2008

New Alzheimer's studies show advances against different treatment targets

Two studies related to experimental Alzheimer's therapies reported positive results today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008) in Chicago.

28 Jul 2008

Tethered bilayer membrane may unlock secrets of early-stage Alzheimer's

Researchers at the National Institute of Standards and Technology (NIST) and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer's disease actually impairs a neuron's structure and function.

23 Jul 2008

Advanced Cancer Therapeutics licenses technology to develop HPV vaccine

Advanced Cancer Therapeutics (ACT) has announced the signing of two new collaborative agreements that will advance development of the Company's novel human papillomavirus (HPV) vaccine program.

23 Jul 2008

Bioscience fund GBS invests US$6m in Xenome

Biopharmaceutical company Xenome Limited today announced it has received a convertible note placement of US$6 million from GBS Venture Partners, a Melbourne based life sciences specialist that invests in unlisted and listed high growth companies involved in innovative technologies.

23 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

Diet alone cannot control type 2 diabetes

Despite strong evidence that type 2 diabetes can be prevented or at least delayed by a combination of lifestyle changes and good dietary advice, a team of Cochrane Researchers found that there is no indication whether dietary advice alone can prevent the disease.

16 Jul 2008

Researchers step closer to delivering cancer-killing drugs to pediatric brain tumors

An interdisciplinary team of researchers at Washington University in St. Louis, led by Karen L. Wooley, Ph.D., James S. McDonnell Distinguished University Professor in Arts & Sciences, is a step closer to delivering cancer-killing drugs to pediatric brain tumors, similar to the tumor that Senator Ted Kennedy is suffering from.

14 Jul 2008

A safe and efficient gene delivery method that doesn't involve viruses

The potential of gene therapy has long been hampered by the risks associated with using viruses as vectors to deliver healthy genes, but a new University of Georgia study helps bring scientists closer to a safe and efficient gene delivery method that doesn't involve viruses.

26 Jun 2008

Discovery of second genetic risk factor for developing late-onset Alzheimer's disease

Researchers have discovered the second, strong genetic risk factor for developing late-onset Alzheimer's disease, according to a new report in the June 27th issue of the journal Cell, a Cell Press publication.

25 Jun 2008

Radioimmunotherapy targeting viral antigens shows potential to treat or prevent viral cancers

A new study, presented at the Society of Nuclear Medicine's 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat-or even prevent-many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.

16 Jun 2008

Peregrine Pharmaceuticals awarded two new U.S. patents for targeted anti-aminophospholipid agents

Peregrine Pharmaceuticals, Inc. today reported the issuance of two U.S. patents that significantly broaden the company's intellectual property leadership in the field of targeted anti-aminophospholipid agents.

16 Jun 2008